While PD-(L)1 inhibitors did not show survival benefits as a single agent or in combination with chemotherapy in patients with recurrent ovarian cancer in phase 3 clinical trials,43–47 this is hypothesized to have resulted from the more highly immunosuppressive tumor microenvironment in the recurrent setting than that in the chemonaïve setting.48 This evidence concerns the gene CD274 and ovarian cancer.